What are the off‑label uses of sildenafil?

Off-Label Uses of Sildenafil

Sildenafil has two FDA-approved indications: erectile dysfunction (25-100 mg doses) and pulmonary arterial hypertension in adults (20 mg TID), but it is extensively used off-label in several clinical scenarios, most notably in pediatric pulmonary hypertension, persistent pulmonary hypertension of the newborn (PPHN), and emerging applications in vascular salvage procedures. 1

FDA-Approved Indications (For Context)

The FDA has approved sildenafil for:

• Erectile dysfunction (25-100 mg formulations)
• Pulmonary arterial hypertension in adults (20 mg TID formulation) 1

The drug improves exercise capacity and slows disease progression in adult PAH by reducing pulmonary vascular resistance through PDE-5 inhibition and cGMP-mediated vasodilation.

Major Off-Label Uses

1. Pediatric Pulmonary Arterial Hypertension

This is the most controversial off-label use. Despite extensive clinical experience and approval by the European Medicines Agency for pediatric use, the FDA issued a warning in 2012 against using sildenafil in children aged 1-17 years due to increased mortality observed during long-term therapy at high doses 2, 3.

Key considerations:

• Low doses appear safer than high doses in pediatric PAH
• Sildenafil monotherapy is likely insufficient as disease progresses
• Close surveillance and frequent monitoring are mandatory
• The warning challenges but does not eliminate its use, as therapeutic options remain extremely limited in this life-threatening condition 2

Clinical reality: Sildenafil continues to be used off-label in pediatric PAH because alternative therapies are scarce, but clinicians must carefully weigh risks versus benefits and avoid high-dose chronic therapy 3.

2. Persistent Pulmonary Hypertension of the Newborn (PPHN)

Sildenafil is used off-label in term and near-term infants with PPHN, particularly in low-resource settings where inhaled nitric oxide is unavailable. 4, 5

Evidence base:

• Four randomized controlled trials (137 subjects total) showed improvements in oxygenation index and reduced mortality (5.9% vs 44% with placebo) in settings without inhaled nitric oxide 4
• Critical caveat: There are NO trials evaluating sildenafil in areas where inhaled nitric oxide is routinely available 4
• One case report demonstrated successful management of PPHN with compounded oral sildenafil when inhaled nitric oxide was unavailable 5

Clinical algorithm:

• First-line: Inhaled nitric oxide remains the standard when available
• Alternative: Oral sildenafil may be considered when inhaled nitric oxide is unavailable or inaccessible
• Caution: Dosing and safety data remain limited, particularly regarding optimal dosing regimens 4

3. Bronchopulmonary Dysplasia (BPD) Prevention in Premature Infants

This use is NOT supported by current evidence and may be harmful. 4

One trial evaluated early sildenafil (after day 7 of life) in 20 premature infants for BPD prevention. Results showed:

• More deaths in the sildenafil group (not statistically significant)
• Increased exposure to postnatal steroids
• Higher right ventricular pressures later in hospitalization 4

Recommendation: Avoid using sildenafil for BPD prevention in premature infants until further safety data are available.

4. BPD-Associated Pulmonary Hypertension in Premature Infants

No controlled trials exist evaluating sildenafil versus placebo in this population. 4 Despite this evidence gap, it is used clinically due to limited alternatives, but this represents truly off-label practice without supporting trial data.

5. Vascular Salvage in Surgical Complications

Emerging evidence suggests sildenafil may salvage compromised tissue perfusion in postoperative settings. 6

A 2025 case series reported successful use of oral sildenafil (20 mg every 6 hours) for areolar venous congestion following breast reduction surgery:

• Two of three patients responded to sildenafil alone
• One required adjunct scarification and heparin therapy
• No arterial damage or major adverse effects observed 6

Mechanism: Enhanced microvascular circulation through PDE-5 inhibition improves venous outflow in compromised tissue.

Clinical application: This represents a non-invasive pharmacologic option for postoperative vascular compromise, though further studies are needed to standardize its use 6.

6. Other Potential Off-Label Uses

The literature suggests sildenafil's PDE-5 inhibition may have therapeutic potential in various pathologies including cancer and neurodegenerative diseases, but these remain investigational without clinical trial support 7.

Critical Safety Warnings for All Off-Label Uses

Absolute contraindications apply regardless of indication:

• Never combine with nitrates (nitroglycerin, isosorbide, "poppers") - can cause life-threatening hypotension 1
• Avoid in patients with severe cardiovascular disease, recent MI, or unstable angina
• Monitor for vision changes (NAION risk) and sudden hearing loss 1

Dose-dependent adverse effects increase at higher doses:

• Flushing, diarrhea, myalgia, visual disturbances
• Retinal hemorrhage (1.4% at 20 mg TID)
• Risk amplified with concurrent anticoagulation 1

Clinical Pitfalls to Avoid

1. Do not use high-dose sildenafil chronically in children - associated with increased mortality 2, 3
2. Do not use sildenafil for BPD prevention in premature infants - potential harm without proven benefit 4
3. Do not assume sildenafil replaces inhaled nitric oxide for PPHN when the latter is available 4
4. Do not use sildenafil as monotherapy for progressive pediatric PAH - requires escalation and combination therapy 2
5. Always verify the patient is not taking nitrates before prescribing for any indication 1